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1. Introduction 
Methylation is one of the major controlling posttranscriptional modification in protein function, 
however the cellular consequences are not well understood yet. Among others its role was 
implyed in gene expression regulation during cellular differentiation, such as  nerve growth factor 
(NGF) mediated neurite outgrowth of PC12 rat pheochromocytoma cell line (Cimato, Ettinger et 
al. 1997). Arginine methylation was found to be more prevalent than carboxylmethylation in this 
process (Cimato, Tang et al. 2002). 
Arginine methylation is catalyzed by protein N-arginine methyltransferases (PRMTs). Two 
different classes of protein arginine methyltransferase enzymes are known. Type I enzymes 
(PRMT1, 3, 4, 6 and 8) catalyze the formation of asymmetric NG,NG-dimethylarginine (aDMA) 
residues while the Type II (PRMT5)  enzymes catalyze the formation of symmetric NG,N'G-
dimethylarginine (sDMA) residues. Both enzyme types generate NG-monomethylarginine 
(MMA) intermediates. The activity of PRMT2, PRMT7 and PRMT9 has not yet been identified 
(reviewed in (Bedford and Clarke 2009) . 
PRMT1 is the major type of protein arginine methyltransferase. PRMT1 null mice are lethal at a 
very early embryonic stage, indicating its essential role in embryonic development (Pawlak, 
Scherer et al. 2000). The same study also revealed the high expression of PRMT1 in vivo in the 
developing nervous system. Futhermore, a recent study already implicated PRMT1  in neurite 
outgrowth of Neuro2a neuroblastoma cells (Miyata, Mori et al. 2008). Homodimerization or 
homooligomerization of the PRMT1 subunit is important for its enzymatic activity (Zhang and 
Cheng 2003). Interestingly, the novel arginine methyltransferase PRMT8 is able to form 
heterodimer with the PRMT1 (Lee, Sayegh et al. 2005). Substrate specificity, cooperation and 
redundancy between the two proteins has not yet been investigated. PRMT8 share more than 80% 
homology with PRMT1, and importantly its expression is primarily limited to the brain. Until 
now, PRMT8 localization has been studied only in mouse central nervous system (Kousaka, Mori 
et al. 2009), but not in the context of developing neurons. 
Importantly, the widely used PC12 cell line and Neuro2a cells resemble sympathetic neurons of 
the peripheral nervous system (PNS), but not of neurons of the central nervous system (CNS). 
Furthermore, such transformed cell lines offer limited possibility to investigate the role of 
PRMTs in progenitors. 
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Mouse embryonic stem (ES) cells are pluripotent cell lines derived from the inner cell mass of 
the blastocyst. ESCs can give rise to neuroectodermal derivatives in culture when treated with all-
trans retinoic acid (ATRA). ATRA and its derivatives are the natural ligand for a class of nuclear 
receptors comprised of two subfamilies: the RARs and the retinoid X receptors (RXRs). 
In the recent study we used first time embryonic stem cell to determine the role of Type I 
arginine methyltransferases in neural differentiation. We identified PRMT1 and PRMT8 as two 
member of Type I arginine methyltransferase showing elevated expression during neurogenesis. 
We have generated PRMT1 and 8 knockdowns Role of PRMT1 was analyzed in details in ES 
cells and early differentiated embryoid bodies using genome-wide analysis. We revealed the role 
of PRMT1 and 8 in retinoic acid induced neural differentiation. 
 
2. Results 
 
PRMT1 and PRMT8 expressions are increased during neural differentiation 
Retinoic acid driven neural differentiation of ES cells has been set up as a model system (Figure 
1A). As a first step we performed western blot analysis using Asym24 antibody that recognize 
asymmetrically arginine methylated proteins. A clear difference can be detected between 
undifferentiated ES cells and neural progenitors (Figure 1B). Proteins with size around 70 kDa, 
presumably the known PRMT methylated Sam68, show increased methylation in ATRA-treated 
samples. In contrast, a protein with size 34 kDa show downregultion during both spontaneous 
and neural differentiation (Figure 1B, 1E). CARM1 (also known as PRMT4) has been shown that 
play crucial role in maintainance of pluripotent phenotype, while a PRMT inhibitor, called AMI-
5 has been recently demonstrated that enables Oct4-induced reprogramming of mouse embryonic 
fibroblasts, suggesting important role of arginine methylation in pluripotent phenotype. To 
unravel which PRMTs are liable for the detected methylation in ES cells we collected data from 
our genome-wide expression analysis that proved the presence of CARM1, PRMT1 and PRMT3. 
As a next step we identified the expressional pattern of Type I PRMTs in neurogenesis. As Figure 
1D and 1E show PRMT1 and PRMT8 are upregulated during neural differentiation. While 
PRMT1 is already expressed in ES cells, PRMT8 can be detected only in late timepoint of the 
differentiation. Appearance of PRMT8 is in correlation with elevated Tuj1 expression. 
 
PRMT1 depletion does not effect the ES pluripotency 
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To elucidate the role of PRMT1 and PRMT8 in neural differentiation we established PRMT1 and 
PRMT8 knockdown ES cells. As PRMT8 is not expressed in ES cells we could only validate the 
PRMT1 knockdown in ESC. Interestingly, loss of PRMT1 leads to significant decrease in total 
asymmetric arginine methylation, with the exception of the ~34 kDa protein. Comparison of 
knockdown and wild-type ES cells showed no alteration in typical ES cell markers, suggesting 
that PRMT1 is not responsible for maintaining pluripotency. The fact, that the ~34 kDa protein 
show stepped decrease during both spontaneous or neural differentiation (Figure 1E) and it is not 
influenced by PRMT1 downregulation may suggest that this protein is methylated by CARM1 
and participate in regulation of pluripotent phenotype. 
PRMT1 show cytoplasmic localization, which raise the hypothesis that in this cell type PRMT1 is 
not participate directly in transcriptional regulation via its coactivator function.  
To further study the role of PRMT1 in undifferentiated cells we performed a genome-wide 
comparison of siPRMT1 and siSCR cells. GO classification of significantly different genes 
suggest the importance of PRMT1 in extracellular matrix and  small nucleolar RNAs. 
However we could detect alteration in several retinoid signaling related genes (Cyp26a1, RXRg, 
Tgm2, etc.) our results excluded the coregulator role of PRMT1 in the retinoid signaling both in 
ES and EB. 
We have also tested the effect of PRMT1 depletion in early spontaneous differentiation (PRMT8 
at this stage is still not expressed). As Figure 2D show, there is no complete block in any main 
lineage differentiation, however the mesoderm differentiation seems more pronounced. 
  
PRMT1 and PRMT8 does not influence significantly ATRA-induced neurite outgrowth 
We have used the generated knockdown cells to compare the differentiation ability of these cells. 
As Figure 3A show the knockdown effect is stable in case of PRMT1 during the 12 day and the 
expression is decreased to half in case of PRMT8. We have also measured the efficiency of 
knockdowns at day 10 on protein level (Figure 3B). 
In contrast with our expectation we could see neurite outgrowth in each case. To exclude that it is 
due to the residual expression of PRMTs, we repeated the experiment using PRMT1 -/- ES cells 
(supplementary). Independently we also tested the effect of AMI-1, a PRMT1 specific inhibitor, 
that resulted similar phenomena (Supplementary). In case of PRMT8 we had no available 
knockout ES cell as a control. However the fact, that PRMT8 full body knockout mice are viable 
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without any significant detectable neurological problem may certify our results. AdOX, a non 
specific arginine methyltransferase inhibitor were toxic for the cells before the cells started to 
differentiate. 
Real-time quantitative PCR (RT-qPCR) indicates that Pax6 (neuronal precursor marker), is 
rapidly induced afer ATRA-treatment in both wild-type, siSCR , siPRMT1 and siPRMT8 cells, 
then show similar decrease in each cell type when neurons differentiate.  Similar expression level 
can be detected in case of other neural markers, such as Tuj1 (Neuron-specific class III beta-
tubulin), Neurog2 (neurogenin 2) and Lhx1 (LIM homeobox 1). These data has been further 
confirmed using AMI-1 treated cells (Supplementary). These results suggest that PRMT1 is not 
essential for neurite outgrowth. PRMT8 is appear 2 days later than Pax6, in the same time as 
Neurog2, Lhx1 and Tuj1 are appearing. 
Based on these results we can conclude that loss of PRMT1 is not blocking any of the 
differentiation pathways.  
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